drugset / Trial / NCT00535665
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
Phase 2
Completed
402 enrolled
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A single center, randomized and double-blind phase II clinical trial is to be conducted in adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine (whole-virion, aluminium-adjuvanted).
Timeline
- Start
- 2007-09
- Primary completion
- —
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 5 ug | — |
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 10 ug | — |
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 15 ug | — |